Novartis team scores a pioneering first in cardio R&D. But can they sell it?
Novartis is facing another blockbuster challenge of global proportions.
How do you market a heart drug with real but clearly limited health benefits? One where …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
